Popat, R., Larson, S. M., Yanovsky, A. V., Bal, S., Raab, M., Grazioli, K., Basudhar, D., Hu, H., Meng, Y., Eldjerou, L., Harrison, S. J., Rodriguez-Otero, P. (2025). QUINTESSENTIAL-2: A phase 3 study comparing efficacy and safety of arlocabtagene autoleucel (arlo-cel) versus standard regimens in adult patients with relapsed or refractory multiple myeloma (RRMM) refractory to lenalidomide.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps7564